New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.
List view / Grid view
Filter the results
Research into drug targets for sleeping sickness parasite T. brucei has characterised the inosine-5'-monophosphate dehydrogenase (IMPDH) enzyme, providing a possible novel avenue for therapies.
Modern day oncology therapies have seen significant innovation in the last decade. It is high time we commit to using biomarkers that are driven by rational design and the latest computational methods.
The systematic successful treatment of cancer still eludes us and in an effort to refine this area of targeted medicine, Lauri Paasonen and colleagues explore the potential of using patient-derived cells (PDCs) for devising a personalised treatment strategy for solid tumours.
We are on the precipice of realising the true potential of genomics studies. Following completion of the Human Genome Project six years ago, huge strides have been made in understanding how the genome works, shedding light on disease pathogenesis and forging therapeutic efforts. In this article, Pushpanathan Muthuirulan explains how…
A study has used CRISPR-Cas9 to treat obesity and type 2 diabetes symptoms in mice, highlighting the potential use in humans.
Next generation molecular medicine: unlocking big data for precision oncology and infectious disease
Join the international [BC]2 conference and EMBO meeting at BASEL LIFE from 9–12 September: a unique opportunity for today’s scientists to get insights and share the latest discoveries, resources and approaches to make sense of genomic and health-related “big data” for molecular medicine – from precision oncology to infectious diseases.
A new study shows the treatment of psychosis can be targeted to a specific genetic mutation in patients with psychotic disorders.
Researchers have, for the first time, duplicated a patient's blood-brain barrier (BBB), creating a human BBB chip with stem cells.
Scientists in the United States have inadvertently uncovered a promising treatment for melanoma that targets the NGLY1 gene.
Researchers in Denmark have developed a method that enables better tailored pharmaceuticals with fewer side effects.
Congestive heart failure is a terminal disease that affects nearly 6 million people in the U.S.; yet its management is limited to symptomatic treatments as its causal mechanisms – including its most common form, ischemic cardiomyopathy – are unknown.
This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.